Welsh CRO accesses new investment fund
The new Wales Life Sciences Investment Fund has made its first investment, backing Merthyr Tydfil-based clinical research organisation Simbec Research.
Read MoreAuthor: Katrina Megget
Affymax future uncertain after job cuts and drug recall
Californian biopharmaceutical company Affymax could be up for grabs after the firm has been forced to fire 75% of its workforce following the recall of its only drug.
Read MoreFDA turns down Pharmaxis cystic fibrosis drug
The US Food and Drug Administration has rejected Pharmaxis’ cystic fibrosis drug Bronchitol because of inadequate trial data.
Read MoreNHS launches health app library
The NHS Commissioning Board has launched a library of NHS-reviewed health apps to help people manage their health.
Read MoreDoctors call for action on tackling the UK’s obesity crisis
A ban on junk food advertisements before 9pm and increased taxes on sugary drinks are two recommendations set out in a new report to tackle obesity in the UK.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
